source
- NewLimit raises $435M Series C to launch epigenetic anti-aging therapy, while Lilly signs GLP-2 obesity drug dealLongevity startup NewLimit announced a $435 million Series C financing, one of the largest biotech rounds this year. The round was led by Founders Fund and included investors such as Thrive Capital…
- Regeneron expands partnership with CytomX as other pharma partners exitRegeneron announced it will deepen its collaboration with CytomX Therapeutics, a Bay Area biotech. The decision follows CytomX losing several partnership agreements with other large pharmaceutical…